Concourse Financial Group Securities, Inc. Ocuphire Pharma, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	N/A	0 New	0 $0
Q1 2025 May 14, 2025	BUY	N/A	0 New	0 $0
Q4 2024 Feb 13, 2025	BUY	$0.88 - $1.35 $0 - $0	0 New	0 $0
Q3 2024 Oct 10, 2024	SELL	$1.19 - $2.07 $865 - $1,504	-727 Closed	0 $0
Q2 2024 Jul 23, 2024	SELL	$1.51 - $2.23 $687 - $1,014	-455 Reduced 38.49%	727 $1,000
Q2 2023 Aug 10, 2023	BUY	$3.63 - $6.38 $4,290 - $7,541	1,182 New	1,182 $5,000
Q1 2023 May 15, 2023	BUY	$3.01 - $3.85 $0 - $0	0 New	0 $0
Q4 2022 Jan 30, 2023	BUY	$2.04 - $3.53 $0 - $0	0 New	0 $0
Q3 2022 Nov 15, 2022	BUY	$1.82 - $2.79 $0 - $0	0 New	0 $0
Q2 2022 Aug 09, 2022	BUY	$1.8 - $3.25 $0 - $0	0 New	0 $0
Q1 2022 May 09, 2022	BUY	$2.75 - $4.39 $0 - $0	0 New	0 $0
Q4 2021 Feb 07, 2022	BUY	$3.4 - $5.19 $0 - $0	0 New	0 $0
Q3 2021 Nov 09, 2021	BUY	$3.84 - $5.38 $0 - $0	0 New	0 $0
Q2 2021 Aug 13, 2021	BUY	$4.24 - $6.57 $0 - $0	0 New	0 $0
Q1 2021 May 13, 2021	BUY	$5.7 - $13.31 $0 - $0	0 New	0 $0
Q4 2020 Feb 02, 2021	BUY	$3.76 - $8.8 $0 - $0	0 New	0 $0

Others Institutions Holding OCUP

# of Institutions

Shares Held

18M

Call Options Held

19K

Put Options Held

Perceptive Advisors LLC New York, NY

4.33M
Shares

$4.24 Million
0.19% of portfolio
Bios Capital Management, LP Fort Worth, TX

3.68M
Shares

$3.61 Million
4.77% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

3.35M
Shares

$3.28 Million
0.14% of portfolio
Vanguard Group Inc Valley Forge, PA

1.34M
Shares

$1.32 Million
0.0% of portfolio
Opaleye Management Inc. Boston, MA

1.22M
Shares

$1.2 Million
0.29% of portfolio

View Full List

About Ocuphire Pharma, Inc.

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

More about OCUP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account